The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion

University of Aarhus

Status: Completed

Conditions: Diabetes Mellitus Type 2

Treatments: Drug: Acipimox

Study type: Interventional

Funder types: Other

Identifiers

NCT02796950

GLP-1-16-02-261-16

Details and patient eligibility

About

Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in the treatment of DM2 (type 2 diabetes mellitus). Recently it was found, that levels of GLP-1 are increased in response to acipimox. The hypothesis is that G protein coupled receptors on enteroendocrine L cells bind acipimox and thereby induce GLP-1 secretion.

In a controlled, open, randomized experiment, eight healthy, overweight men will be studied on an intervention day, where they receive acipimox, and on a control day. The study day includes an OGTT (oral glucose tolerance test), blood samples before and after the OGTT and a biopsy from adipose tissue.

Enrollment: 8 patients

Sex: Male

Ages: 20 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adult men
• Healthy
• BMI 25-35

Exclusion criteria

• Known DM2
• Receiving hypolipidemic drugs

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

8 participants in 2 patient groups

Acipimox

Experimental group

Description:

Administration of acipimox 250 mg p.o.

Treatment:

Drug: Acipimox

Control

No Intervention group

Description:

No intervention.